Int J Cancer 1998, 77:361–365.PubMedCrossRef 23. Cammarota T: Ecografia in Dermatologia. Poletto Editore, Milano; 1998. 24. Barillari G, Ensoli B: Angiogenic effects of extracellular human immodeficiency virus type1 Tat protein and its role in the pathogenesis of AIDS-associated Kaposi’s Sarcoma. Clin Microbiol Rev 2002, 15:310–326.PubMedCrossRef 25. Pyakurel P, Pak F, Mwakigonja AR, Kaaya E, Biberfeld P: KSHV/HHV-8 and HIV infection in Kaposi’s sarcoma development. Infect Agent Cancer 2007, 2:2–4.CrossRef Competing interests The authors declare that they have no competing interests. Authors’ contributions FMS conceived of the

study and participated in its design and coordination. AL made the clinical diagnosis and the

follow up of patients. FE performed the ultrasound and color Doppler analysis. PCF carried out the immunological and virological determinations. IWR-1 chemical structure CC performed the histological diagnosis. ADC coordinated the study. All authors read and approved the final manuscript”
“Background Anthracyclines are among the most active drugs in advanced breast cancer, with response rates as single agents of approximately Stattic datasheet 30% to 50%, and anthracycline-based regimens have been shown to determine significant advantages in response rate and progression free survival over non- anthracycline-containing regimens [1, 2]. The potential benefit of conventional anthracyclines, mainly doxorubicin, is limited by the risk of cardiac dysfunction, clearly related to cumulative dose, and as a result it might be necessary to withdraw treatment or to avoid re-treatment even in potential responders patients. To minimize toxic effects, doxorubicin has often been replaced by epirubicin (EPI), known to be as active as the parent compound and with lower toxicity, particularly cardiac toxicity [3–6]. As dose-response concerns, higher EPI doses, both as single agent and in combination regimens, seem to be more efficacious than Interleukin-3 receptor lower doses [7–10]. Vinorelbine (VNB) has established activity as single-agent in breast cancer,

both as first-line and salvage treatment [11, 12], and its good tolerance profile makes it an excellent candidate for combination regimens, so it was a logical step to www.selleckchem.com/small-molecule-compound-libraries.html combine VNB with anthracyclines, and the combination with doxorubicin yielded a 74% of response rate, a median duration of response of 12 months and a median survival of 27.5 months as first-line treatment [13]. Other trials employing this combinations confirmed positive results [14–16]. Preliminary results of a randomized phase III trial comparing VNB 25 mg/m2 on days 1,8 in combination with EPI 90 mg/m2, with EPI as single agent, showed a trend for higher response rate (50% vs 42%) and a significantly longer progression free survival (10.1 vs 8.2 months) for the combination arm [17].